Author: OurCrowd

[Dandelion Energy in PR Newswire] Dandelion Energy urges New York Senate to pass new geothermal legislation to update regulations and save homeowners money on heating and cooling

May 25, 2023 |

MOUNT KISCO, N.Y., May 25, 2023 /PRNewswire/ — Dandelion Energy, the nation’s leading home geothermal company, urges the New York Senate to pass S6604 as soon as possible, following the bipartisan approval in the Senate Committee on Environmental Conservation earlier this week and passage of companion legislation A6949 by the full New York Assembly last week. Read...

Read More

[Biolojic in BioSpace] Interim results from phase 1/2 clinical trial in solid tumor cancers demonstrate Aulos Bioscience’s AU-007 is well tolerated and uniquely reduces regulatory T Cells

May 25, 2023 |

LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today shared interim results from an ongoing Phase 1/2 trial of AU-007, as detailed in the online publication of Abstract e14507 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. Read...

Read More

[InsideTracker in PR Newswire] Maximize your sleep to enhance your healthspan: Industry pioneers InsideTracker and ŌURA launch highly anticipated integration

May 25, 2023 |

CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ — InsideTracker, the leading personal health analysis and data-driven wellness guide that helps people increase their healthspan and live healthier longer, announced today the highly anticipated integration with ŌURA, the company behind Oura Ring—the smart ring that delivers continuous and personalized health data, insights, and daily guidance. Read more...

Read More

[MeMed in GlobeNewswire] MeMed: Nutex Health Announces Agreement with MeMed to Adopt Pioneering MeMed BV® Test Across its Network of 19 sites

May 25, 2023 |

HOUSTON and HAIFA, Israel, May 25, 2023 – Nutex Health Inc. (“Nutex Health”) (NASDAQ: NUTX), a distinguished physician-led, technology-enabled integrated healthcare delivery system, and MeMed, a pioneer in the burgeoning field of advanced host response technologies, announce today a strategic partnership that expands access to the trailblazing MeMed BV test. The test distinguishes viral from bacterial infections in 15 minutes and applies machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed’s technology helps physicians enhance patient management and make better informed antibiotic treatment decisions. Read more...

Read More